Stryker (SYK) Competitors

Stryker (NYSE:SYK) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and community ranking.

Is SYK or BSX more profitable?

Stryker has a net margin of 13.86% compared to Boston Scientific's net margin of 6.91%. Stryker's return on equity of 22.17% beat Boston Scientific's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stryker	13.86%	22.17%	9.99%
Boston Scientific	6.91%	14.57%	7.94%

Do institutionals and insiders believe in SYK or BSX?

77.1% of Stryker shares are owned by institutional investors. Comparatively, 90.2% of Boston Scientific shares are owned by institutional investors. 5.9% of Stryker shares are owned by insiders. Comparatively, 0.7% of Boston Scientific shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Does the media favor SYK or BSX?

In the previous week, Boston Scientific had 3 more articles in the media than Stryker. MarketBeat recorded 16 mentions for Boston Scientific and 13 mentions for Stryker. Boston Scientific's average media sentiment score of 0.60 beat Stryker's score of 0.60 indicating that Boston Scientific is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stryker	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Boston Scientific	5 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer SYK or BSX?

Boston Scientific received 83 more outperform votes than Stryker when rated by MarketBeat users. Likewise, 69.51% of users gave Boston Scientific an outperform vote while only 64.45% of users gave Stryker an outperform vote.

Company	Underperform	Outperform
Stryker	Outperform Votes 861 64.45%	Underperform Votes 475 35.55%
Boston Scientific	Outperform Votes 944 69.51%	Underperform Votes 414 30.49%

Do analysts prefer SYK or BSX?

Stryker presently has a consensus target price of $302.00, indicating a potential upside of 8.46%. Boston Scientific has a consensus target price of $54.00, indicating a potential upside of 4.77%. Given Stryker's higher probable upside, equities research analysts plainly believe Stryker is more favorable than Boston Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stryker	0 Sell rating(s)	8 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.60
Boston Scientific	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	3.00

Which has preferable valuation and earnings, SYK or BSX?

Stryker has higher revenue and earnings than Boston Scientific. Stryker is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stryker	$18.45 billion	5.74	$2.36 billion	$6.87	40.69
Boston Scientific	$12.68 billion	5.70	$698 million	$0.59	87.51

Which has more volatility and risk, SYK or BSX?

Stryker has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.

Summary

Stryker beats Boston Scientific on 10 of the 19 factors compared between the two stocks.